Search

Your search keyword '"Gentile, Massimo"' showing total 982 results
Start Over Author "Gentile, Massimo" Publication Year Range Last 10 years
982 results on '"Gentile, Massimo"'

2. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands

Author

Tissino, Erika, Gaglio, Annalisa, Nicolò, Antonella, Pozzo, Federico, Bittolo, Tamara, Rossi, Francesca Maria, Bomben, Riccardo, Nanni, Paola, Cattarossi, Ilaria, Zaina, Eva, Zimbo, Anna Maria, Ianna, Giulia, Capasso, Guido, Forestieri, Gabriela, Moia, Riccardo, Datta, Moumita, Härzschel, Andrea, Olivieri, Jacopo, D’Arena, Giovanni, Laurenti, Luca, Zaja, Francesco, Chiarenza, Annalisa, Palumbo, Giuseppe A., Martino, Enrica Antonia, Gentile, Massimo, Rossi, Davide, Gaidano, Gianluca, Del Poeta, Giovanni, Laureana, Roberta, Del Principe, Maria Ilaria, Maity, Palash C., Jumaa, Hassan, Hartmann, Tanja Nicole, Zucchetto, Antonella, and Gattei, Valter

Published
2024
Full Text
View/download PDF

3. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study

Author

Leotta, Salvatore, Markovic, Uros, Duminuco, Andrea, Mulè, Antonino, Porretto, Ferdinando, Federico, Vincenzo, Gentile, Massimo, Pastore, Domenico, Nigro, Luca Lo, Selleri, Carmine, Serio, Bianca, Calafiore, Valeria, Patti, Caterina, Mauro, Elisa, Vetro, Calogero, Maugeri, Cinzia, Parisi, Marina, Fiumara, Paolo, Parrinello, Laura, Marino, Sara, Scuderi, Grazia, Garibaldi, Bruno, Musso, Maurizio, Renzo, Nicola Di, Vigna, Ernesto, Martino, Enrica Antonia, Raimondo, Francesco Di, and Milone, Giuseppe

Published
2024
Full Text
View/download PDF

4. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience

Author

Mele, Giuseppe, Derudas, Daniele, Conticello, Concetta, Barilà, Gregorio, Gentile, Massimo, Rocco, Stefano, Palmieri, Salvatore, Palazzo, Giulia, Germano, Candida, Reddiconto, Giovanni, Sgherza, Nicola, De Novellis, Danilo, Galeone, Carlotta, Castiglioni, Sara Agavni’, Deiana, Luca, Pascarella, Anna, Martino, Enrica Antonia, Foggetti, Ilaria, Blasi, Ilenia, Spina, Alessandro, Di Renzo, Nicola, Maggi, Alessandro, Tarantini, Giuseppe, Di Raimondo, Francesco, Specchia, Giorgina, Musto, Pellegrino, and Pastore, Domenico

Published
2024
Full Text
View/download PDF

5. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Author

Botta, Cirino, Perez, Cristina, Larrayoz, Marta, Puig, Noemi, Cedena, Maria-Teresa, Termini, Rosalinda, Goicoechea, Ibai, Rodriguez, Sara, Zabaleta, Aintzane, Lopez, Aitziber, Sarvide, Sarai, Blanco, Laura, Papetti, Daniele M., Nobile, Marco S., Besozzi, Daniela, Gentile, Massimo, Correale, Pierpaolo, Siragusa, Sergio, Oriol, Albert, González-Garcia, Maria Esther, Sureda, Anna, de Arriba, Felipe, Rios Tamayo, Rafael, Moraleda, Jose-Maria, Gironella, Mercedes, Hernandez, Miguel T., Bargay, Joan, Palomera, Luis, Pérez-Montaña, Albert, Goldschmidt, Hartmut, Avet-Loiseau, Hervé, Roccaro, Aldo, Orfao, Alberto, Martinez-Lopez, Joaquin, Rosiñol, Laura, Lahuerta, Juan-José, Blade, Joan, Mateos, Maria-Victoria, San-Miguel, Jesús F., Martinez Climent, Jose-Angel, and Paiva, Bruno

Published
2023
Full Text
View/download PDF

6. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial

Author

Mazzucconi, Maria Gabriella, Rodeghiero, Francesco, Avvisati, Giuseppe, De Stefano, Valerio, Gugliotta, Luigi, Ruggeri, Marco, Vianelli, Nicola, Fazi, Paola, Paoloni, Francesca, Sargentini, Valeria, Baldacci, Erminia, Ferretti, Antonietta, Martino, Bruno, Vincelli, Iolanda Donatella, Carli, Giuseppe, Fortuna, Stefania, Di Ianni, Mauro, Ranalli, Paola, Palandri, Francesca, Polverelli, Nicola, Lugli, Elisabetta, Rivolti, Elena, Patriarca, Andrea, Rago, Angela, D’Adda, Mariella, Gentile, Massimo, Siragusa, Sergio, Sibilla, Silvia, Carella, Angelo Michele, Rossi, Elena, Battistini, Roberta, Zaja, Francesco, Bocchia, Monica, Di Renzo, Nicola, Musto, Pellegrino, Crugnola, Monica, Giuffrida, Anna Chiara, Krampera, Mauro, Tafuri, Agostino, and Santoro, Cristina

Published
2024
Full Text
View/download PDF

7. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, Riccardo, Rossi, Francesca Maria, Vit, Filippo, Bittolo, Tamara, Zucchetto, Antonella, Papotti, Robel, Tissino, Erika, Pozzo, Federico, Degan, Massimo, Polesel, Jerry, Bulian, Pietro, Marasca, Roberto, Reda, Gianluigi, Laurenti, Luca, Olivieri, Jacopo, Chiarenza, Annalisa, Laureana, Roberta, Postorino, Massimiliano, Del Principe, Maria Ilaria, Cuneo, Antonio, Gentile, Massimo, Morabito, Fortunato, Fronza, Gilberto, Tafuri, Agostino, Zaja, Francesco, Foà, Robin, Di Raimondo, Francesco, Del Poeta, Giovanni, and Gattei, Valter

Published
2023
Full Text
View/download PDF

8. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

Author

Oliva, Stefania, Genuardi, Elisa, Paris, Laura, D'Agostino, Mattia, Rogers, Jennifer, Rota-Scalabrini, Delia, Jacob, Allison P., Patriarca, Francesca, Luppi, Mario, Bertazzoni, Paola, Velluti, Cristina, Capra, Andrea, Saraci, Elona, Rossi, Marco, Allegra, Alessandro, Mina, Roberto, Gentile, Massimo, Kirsch, Ilan R., Belotti, Angelo, Cavo, Michele, Bruno, Benedetto, Musto, Pellegrino, Boccadoro, Mario, Zamagni, Elena, and Gay, Francesca

Published
2023
Full Text
View/download PDF

10. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

Author

Matis, Serena, Grazia Recchia, Anna, Colombo, Monica, Cardillo, Martina, Fabbi, Marina, Todoerti, Katia, Bossio, Sabrina, Fabris, Sonia, Cancila, Valeria, Massara, Rosanna, Reverberi, Daniele, Emionite, Laura, Cilli, Michele, Cerruti, Giannamaria, Salvi, Sandra, Bet, Paola, Pigozzi, Simona, Fiocca, Roberto, Ibatici, Adalberto, Angelucci, Emanuele, Gentile, Massimo, Monti, Paola, Menichini, Paola, Fronza, Gilberto, Torricelli, Federica, Ciarrocchi, Alessia, Neri, Antonino, Fais, Franco, Tripodo, Claudio, Morabito, Fortunato, Ferrarini, Manlio, and Cutrona, Giovanna

Published
2022
Full Text
View/download PDF

11. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

12. The role of corticosteroids in the current treatment paradigm for myelofibrosis.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Rossi, Teresa, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
CORTICOSTEROIDS, MYELOFIBROSIS, BONE marrow, THERAPEUTICS, IMMUNOREGULATION, CYTOKINES
Abstract

Introduction: Myelofibrosis (MF) is a clonal hematological disorder characterized by bone marrow fibrosis, splenomegaly, and inflammatory cytokine dysregulation. While the role of steroids in MF is not fully defined, their anti-inflammatory properties may offer therapeutic benefits, particularly in managing anemia and other cytopenias. Steroids exert their effects by suppressing pro-inflammatory cytokines such as IL1, IL6, and TNF, and by enhancing anti-inflammatory cytokines like IL4 and IL10. Elevated levels of IL6 and other cytokines in MF are associated with anemia and poor prognosis, suggesting that steroid therapy could mitigate these effects. Areas covered: In this manuscript, we review clinical studies which evaluated the safety and efficacy of steroids in MF patients. Moreover, we examine clinical data of the combination of steroids with immunomodulatory agents and JAK inhibitors. Our literature search consisted of an extensive review of PubMed and clinicaltrials.gov. Expert opinion: The role of steroids in the management of MF remains poorly defined, though emerging evidence suggests a potential therapeutic benefit, particularly in managing anemia and other cytopenias. The combination with IMIDs has also yielded positive outcomes as demonstrated in several studies. Steroids may also play a crucial role in managing cytopenias in MF patients receiving JAKi. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.

Author

Nano, Ennio, Reggiani, Francesco, Amaro, Adriana Agnese, Monti, Paola, Colombo, Monica, Bertola, Nadia, Ferrero, Fabiana, Fais, Franco, Bruzzese, Antonella, Martino, Enrica Antonia, Vigna, Ernesto, Puccio, Noemi, Pistoni, Mariaelena, Torricelli, Federica, D'Arrigo, Graziella, Greco, Gianluigi, Tripepi, Giovanni, Adornetto, Carlo, Gentile, Massimo, and Ferrarini, Manlio

Subjects
CHRONIC lymphocytic leukemia, PROGNOSTIC models, ARTIFICIAL intelligence, MICRORNA, FUNCTIONAL analysis
Abstract

A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.e., Rai stage, beta-2-microglobulin levels, IGVH mutational status, del11q, del17p, and NOTCH1 mutations) maintained significant associations with TTFT in a basic multivariable model, collectively yielding a Harrell's C-index of 75% and explaining 45.4% of the variance in the prediction of TTFT. Concerning miRNAs, 73 out of 513 were significantly associated with TTFT in a univariable model; of these, 16 retained an independent relationship with the outcome in a multivariable analysis. For 8 of these (i.e., miR-582-3p, miR-33a-3p, miR-516a-5p, miR-99a-5p, and miR-296-3p, miR-502-5p, miR-625-5p, and miR-29c-3p), a lower expression correlated with a shorter TTFT, whereas in the remaining eight (i.e., miR-150-5p, miR-148a-3p, miR-28-5p, miR-144-5p, miR-671-5p, miR-1-3p, miR-193a-3p, and miR-124-3p), the higher expression was associated with shorter TTFT. Integrating these miRNAs into the basic model significantly enhanced predictive accuracy, raising the Harrell's C-index to 81.1% and the explained variation in TTFT to 63.3%. Moreover, the inclusion of the miRNA scores enhanced the integrated discrimination improvement (IDI) and the net reclassification index (NRI), underscoring the potential of miRNAs to refine CLL prognostic models and providing insights for clinical decision-making. In silico analyses on the differently expressed miRNAs revealed their potential regulatory functions of several pathways, including those involved in the therapeutic responses. To add a biological context to the clinical evidence, an miRNA–mRNA correlation analysis revealed at least one significant negative correlation between 15 of the identified miRNAs and a set of 50 artificial intelligence (AI)-selected genes, previously identified by us as relevant for TTFT prediction in the same cohort of CLL patients. In conclusion, the identification of specific miRNAs as predictors of TTFT holds promise for enhancing risk stratification in CLL to predict therapeutic needs. However, further validation studies and in-depth functional analyses are required to confirm the robustness of these observations and to facilitate their translation into meaningful clinical utility. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Author

Botta, Cirino, Maia, Catarina, Garcés, Juan-José, Termini, Rosalinda, Perez, Cristina, Manrique, Irene, Burgos, Leire, Zabaleta, Aintzane, Alignani, Diego, Sarvide, Sarai, Merino, Juana, Puig, Noemi, Cedena, María-Teresa, Rossi, Marco, Tassone, Pierfrancesco, Gentile, Massimo, Correale, Pierpaolo, Borrello, Ivan, Terpos, Evangelos, Jelinek, Tomas, Paiva, Artur, Roccaro, Aldo, Goldschmidt, Hartmut, Avet-Loiseau, Hervé, Rosinol, Laura, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Lahuerta, Juan-José, Bladé, Joan, San-Miguel, Jesús F., and Paiva, Bruno

Published
2022
Full Text
View/download PDF

15. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2021
Full Text
View/download PDF

16. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Stanzione, Gaia, additional, Zimbo, Annamaria, additional, Lugli, Elisabetta, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

17. Momelotinib in myelofibrosis

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Fragliasso, Valentina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

18. Selinexor in multiple myeloma

Author

Martino, Enrica Antonia, primary, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Torricelli, Federica, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

19. Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients

Author

Leotta, Salvatore, primary, Markovic, Uros, additional, Duminuco, Andrea, additional, Mulè, Antonino, additional, Porretto, Ferdinando, additional, Federico, Vincenzo, additional, Gentile, Massimo, additional, Pastore, Domenico, additional, Nigro, Luca Lo, additional, Selleri, Carmine, additional, Serio, Bianca, additional, Calafiore, Valeria, additional, Patti, Caterina, additional, Mauro, Elisa, additional, Vetro, Calogero, additional, Maugeri, Cinzia, additional, Parisi, Marina, additional, Fiumara, Paolo, additional, Parrinello, Laura, additional, Marino, Sara, additional, Scuderi, Grazia, additional, Garibaldi, Bruno, additional, Musso, Maurizio, additional, Renzo, Nicola Di, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Raimondo, Francesco Di, additional, and Milone, Giuseppe, additional

Published
2024
Full Text
View/download PDF

20. Mosunetuzumab for the treatment of follicular lymphoma

Author

Labanca, Caterina, Martino, Enrica Antonia, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, De Luca, Paola, Lucia, Eugenio, Olivito, Virginia, Fragliasso, Valentina, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Abstract

ABSTRACTIntroductionFollicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history and a median survival of approximately 18–20 years. The advent of anti-CD20 monoclonal antibodies has changed the FL therapeutic algorithm, with an increase in progression-free survival. T-cell-dependent bispecific antibodies (BsAbs) represent an emerging drug class against FL.Areas coveredIn this review, we selected papers from the principal databases (PubMed, Medline, Medscape, ASCO, ESMO) between January 2021 and June 2024, using the keywords ‘mosunetuzumab’ and ‘follicular lymphoma’ to provide an overview of mosunetuzumab-axgb, a pioneering BsAb. Its mechanism of action, efficacy, safety, and future perspectives were analyzed.Expert opinionMosunetuzumab grants a directing T-cell mediated cytotoxicity and allows a step-up dosing that reduces adverse events, such as cytokine release syndrome, with promising tolerability. At the same time, it improves outcomes in the evolving landscape of FL management, even in post-CAR-T FL patients. Prognostic factors and targetable mechanisms of resistance need to be explored.

Published
2024
Full Text
View/download PDF

21. Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Stanzione, Gaia, Zimbo, Annamaria, Pozzi, Stefano, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Abstract

ABSTRACTIntroductionCXCR4/CXCL12 axis regulates cell proliferation, survival, and differentiation, as well as the homing and mobilization of hematopoietic stem cells (HSCs) from bone marrow niches to the peripheral blood. Furthermore, CXCR4 and CXCL12 are key mediators of cross-talk between hematological malignancies and their microenvironments. CXCR4 overexpression drives disease progression, boosts tumor cell survival, and promotes chemoresistance, leading to poor prognosis.Areas coveredIn light of these discoveries, scientific investigations, and clinical trials have underscored the therapeutic promise found in small-molecule antagonists like plerixafor, peptides/peptidomimetics, such as BKT140, monoclonal antibodies like PF-06747143 and ulocuplumab, as well as microRNAs. Their efficacy is evident in reducing tumor burden, inducing apoptosis and sensitizing malignant cells to conventional chemotherapies. This overview delves into the pathogenic role of the CXC4/CXCL12 axis in hematological neoplasms and examines the clinical application of key CXCR4 antagonists.Expert opinionThe information collectively emphasizes the potential of CXCR4 antagonists as a therapeutic strategy for hematologic malignancies, showcasing advancements in preclinical and clinical studies. As these therapeutic strategies progress through clinical trials, their potential to reshape the prognosis of hematologic malignancies will become increasingly apparent.

Published
2024
Full Text
View/download PDF

22. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety

Author

Martino, Massimo, Naso, Virginia, Porto, Gaetana, Paviglianiti, Annalisa, Ferreri, Anna, Loteta, Barbara, Moscato, Tiziana, Console, Giuseppe, Gentile, Massimo, Rossi, Marco, Provenzano, Pasquale Fabio, Gori, Mercedes, Pitino, Anna Lisa, Morabito, Antonella, and Tripepi, Giovanni

Published
2020
Full Text
View/download PDF

24. Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.

Author

Gigliotta, Emilia, Plano, Federica, Corsale, Giusy, Corsale, Anna Maria, Aquilina, Cristina, Speciale, Maria, Rizzuto, Andrea, Martino, Enrica Antonia, Leotta, Dario, Solimando, Antonio Giovanni, Ria, Roberto, Gentile, Massimo, Siragusa, Sergio, and Botta, Cirino

Subjects
PLASMA cells, BONE marrow cells, BODY mass index, MULTIPLE myeloma, OVERALL survival
Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. Recent advancements in anti-CD38 monoclonal antibody therapies, such as daratumumab and isatuximab, have significantly improved MM patient survival. However, the lack of predictive factors of response to these therapies remains a challenge. Notably, anti-CD38 antibodies can interfere with laboratory tests, complicating response assessment. We conducted a retrospective study to evaluate the association between the appearance of positive IgGk (therapeutic antibody) on immunofixation/immunosubtraction (IF) and clinical parameters in 87 non-IgGk MM patients treated with anti-CD38 therapy. Positive IgGk IF was observed in 42 patients after a median of three treatment courses. Patients with positive IgGk IF had higher rates of complete/very good partial responses (p = 0.03) and improved progression-free survival (median not reached vs. 21.83 months, p < 0.01). High BMI (p = 0.03), higher hemoglobin (p = 0.02), lower CRP (p = 0.04), and lower monoclonal protein levels (p = 0.03) were associated with positive IgGk IF. Our findings suggest that monitoring therapeutic antibody appearance on IF may predict and optimize anti-CD38 therapy in MM. Potential explanations include the impact of patient factors (e.g. BMI) on drug pharmacokinetics, the relationship between antibody levels and immune response, and the influence of tumor biology. Further research is needed to elucidate the underlying mechanisms and clinical utility of this biomarker. Nonetheless, our results highlight the importance of considering therapeutic antibody detection when interpreting laboratory tests and managing MM patients receiving anti-CD38 therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.

Author

Urso, Antonio, Martino, Enrica Antonia, Cuneo, Antonio, Gentile, Massimo, and Rigolin, Gian Matteo

Subjects
THERAPEUTIC use of antineoplastic agents, CHRONIC lymphocytic leukemia, GENOMICS, IMMUNOGLOBULINS, TREATMENT effectiveness, KARYOTYPES, BIOMARKERS
Abstract

Simple Summary: The treatment of chronic lymphocytic leukemia (CLL) has dramatically changed following the availability of new drugs with targeted mechanisms of action. Traditional and new prognostic factors are being investigated to individualize and guide these new treatments. In this review, we discuss the clinical relevance of genomic factors including immunoglobulin heavy chain variable (IGHV) mutational status, TP53 abnormalities, complex karyotype, and prognostic scores in relation to new targeted agents. Novel drugs have profoundly changed the outcomes in chronic lymphocytic leukemia (CLL) patients, and the traditional prognostic factors that were identified in the era of chemoimmunotherapy need to be validated in the context of these new targeted therapies. Currently, the most important prognostic genetic biomarkers are the immunoglobulin heavy chain variable (IGHV) mutational status, genetic aberrations including del(17p)/TP53 abnormalities, and the complex karyotype. In this review, we discuss the prognostic role of these genomic markers in relation to novel treatments. Moreover, we present and discuss new scoring systems that were elaborated and validated in the era of new drugs. In routine clinical practice, the application of an extensive genomic work-up with validated prognostic markers could improve the identification of "very high-risk" CLL patients who could benefit from novel, more effective targeted treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Capodanno, Isabella, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
MYELODYSPLASTIC syndromes, ACUTE leukemia, NATURAL immunity, BONE marrow, LENALIDOMIDE, MYELOFIBROSIS
Abstract

Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with del(5q) being the most prevalent. Since its first description, del(5q) was consistently correlated with a typical clinical phenotype marked by anemia, thrombocytosis, and a low risk of evolving into acute leukemia. Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as "myelodysplastic neoplasm with low blast and isolated del(5q)" identified by the sole presence of 5q deletion or in combination with one other abnormality excluding −7/del(7q). Several studies have sought to unravel the biological processes triggered by del(5q) in the development of MDS, revealing the involvement of various genes localized in specific regions of chromosome 5 referred to as common deleted regions (CDR). This intricate biological landscape makes the MDS cells with del(5q) exceptionally sensitive to lenalidomide. Several studies have confirmed the efficacy of lenalidomide in this context. Regrettably, the response to lenalidomide is not conclusive, prompting ongoing research into biological mechanisms that drive patients toward leukemia and strategies to circumvent lenalidomide resistance and disease progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, Francesco, Cattaneo, Chiara, Arcaini, Luca, Bruna, Riccardo, Cavo, Michele, Merli, Francesco, Angelucci, Emanuele, Krampera, Mauro, Cairoli, Roberto, Della Porta, Matteo Giovanni, Fracchiolla, Nicola, Ladetto, Marco, Gambacorti Passerini, Carlo, Salvini, Marco, Marchetti, Monia, Lemoli, Roberto, Molteni, Alfredo, Busca, Alessandro, Cuneo, Antonio, Romano, Alessandra, Giuliani, Nicola, Galimberti, Sara, Corso, Alessandro, Morotti, Alessandro, Falini, Brunangelo, Billio, Atto, Gherlinzoni, Filippo, Visani, Giuseppe, Tisi, Maria Chiara, Tafuri, Agostino, Tosi, Patrizia, Lanza, Francesco, Massaia, Massimo, Turrini, Mauro, Ferrara, Felicetto, Gurrieri, Carmela, Vallisa, Daniele, Martelli, Maurizio, Derenzini, Enrico, Guarini, Attilio, Conconi, Annarita, Cuccaro, Annarosa, Cudillo, Laura, Russo, Domenico, Ciambelli, Fabrizio, Scattolin, Anna Maria, Luppi, Mario, Selleri, Carmine, Ortu La Barbera, Elettra, Ferrandina, Celestino, Di Renzo, Nicola, Olivieri, Attilio, Bocchia, Monica, Gentile, Massimo, Marchesi, Francesco, Musto, Pellegrino, Federici, Augusto Bramante, Candoni, Anna, Venditti, Adriano, Fava, Carmen, Pinto, Antonio, Galieni, Piero, Rigacci, Luigi, Armiento, Daniele, Pane, Fabrizio, Oberti, Margherita, Zappasodi, Patrizia, Visco, Carlo, Franchi, Matteo, Grossi, Paolo Antonio, Bertù, Lorenza, Corrao, Giovanni, Pagano, Livio, and Corradini, Paolo

Published
2020
Full Text
View/download PDF

28. Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity

Author

Torcasio, Roberta, primary, Gallo Cantafio, Maria Eugenia, additional, Veneziano, Claudia, additional, De Marco, Carmela, additional, Ganino, Ludovica, additional, Valentino, Ilenia, additional, Occhiuzzi, Maria Antonietta, additional, Perrotta, Ida Daniela, additional, Mancuso, Teresa, additional, Conforti, Filomena, additional, Rizzuti, Bruno, additional, Martino, Enrica Antonia, additional, Gentile, Massimo, additional, Neri, Antonino, additional, Viglietto, Giuseppe, additional, Grande, Fedora, additional, and Amodio, Nicola, additional

Published
2024
Full Text
View/download PDF

30. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

31. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Author

Martino, Enrica Antonia, primary, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Laurenti, Luca, additional, Visentin, Andrea, additional, Frustaci, Annamaria, additional, Vigna, Ernesto, additional, Pepe, Sara, additional, Catania, Gioacchino, additional, Loseto, Giacomo, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sportoletti, Paolo, additional, Del Principe, Maria Ilaria, additional, Laureana, Roberta, additional, Coscia, Marta, additional, Galimberti, Sara, additional, Ferretti, Eleonora, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Polesel, Jerry, additional, Tedeschi, Alessandra, additional, Rossi, Davide, additional, Trentin, Livio, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

32. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

33. Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

Author

Merli, Michele, Luminari, Stefano, Farina, Lucia, Cocito, Federica, Defrancesco, Irene, Gini, Guido, Arcari, Annalisa, Scapinello, Greta, Gentile, Massimo, Goldaniga, Maria, Loseto, Giacomo, Cencini, Emanuele, Greco, Antonino, Molinari, Anna Lia, Ferrario, Andrea, Bianchi, Benedetta, Mora, Barbara, Bertù, Lorenza, Saturni, Vincenzo, Bergamini, Fabio, Fabbri, Nicole, Rossi, Francesca Gaia, Bolis, Silvia, Passamonti, Francesco, and Arcaini, Luca

Published
2020
Full Text
View/download PDF

34. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Published
2020
Full Text
View/download PDF

35. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Author

Frigeni, Marco, Besson, Caroline, Visco, Carlo, Fontaine, Helene, Goldaniga, Maria, Visentini, Marcella, Pulsoni, Alessandro, Torres, Harrys A., Peveling-Oberhag, Jan, Rossotti, Roberto, Zaja, Francesco, Rigacci, Luigi, Merli, Michele, Dorival, Céline, Alric, Camille, Piazza, Francesco, Gentile, Massimo, Ferrari, Angela, Pirisi, Mario, Nassi, Luca, Rattotti, Sara, Frustaci, Annamaria, Milella, Michele, Cencini, Emanuele, Defrancesco, Irene, Ferretti, Virginia Valeria, Bruno, Raffaele, Hermine, Olivier, and Arcaini, Luca

Published
2020
Full Text
View/download PDF

36. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Author

Martino, Massimo, Gori, Mercedes, Tripepi, Giovanni, Recchia, Anna Grazia, Cimminiello, Michele, Provenzano, Pasquale Fabio, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Loteta, Barbara, Gallo, Giuseppe Alberto, Gentile, Massimo, Innao, Vanessa, Rossi, Marco, Morabito, Antonella, Vincelli, Iolanda Donatella, Mannina, Donato, and Pitino, Annalisa

Published
2020
Full Text
View/download PDF

38. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts

Author

Martino, Massimo, Gori, Mercedes, Moscato, Tiziana, Naso, Virginia, Ferreri, Anna, Provenzano, Fabio, Loteta, Barbara, Sanguedolce, Maria Cristina, Console, Giuseppe, Dattola, Antonia, Pucci, Giulia, Gentile, Massimo, Morabito, Antonella, Recchia, Anna Grazia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2019
Full Text
View/download PDF

39. Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment—67 Patients Multicenter Analysis.

Author

Charliński, Grzegorz, Steinhardt, Maximilian, Rasche, Leo, Gonzalez-Calle, Veronica, Peña, Camila, Parmar, Harsh, Wiśniewska-Piąty, Katarzyna, Dávila Valls, Julio, Olszewska-Szopa, Magdalena, Usnarska-Zubkiewicz, Lidia, Gozzetti, Alessandro, Ciofini, Sara, Gentile, Massimo, Zamagni, Elena, Kurlapski, Michał, Legieć, Wojciech, Vesole, David H., and Jurczyszyn, Artur

Subjects
CARDIAC amyloidosis, IMMUNOGLOBULIN light chains, SYMPTOMS, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, RESEARCH, MEDICAL records, ACQUISITION of data, CONFIDENCE intervals, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Light-chain amyloidosis (AL) is a rare multisystem disorder. One of the most common organs involved in AL is the heart. We conducted a multi-center, retrospective analysis of 67 patients with the European 2012 modification of Mayo 2004 stage III cardiac AL. The prognosis of patients with advanced cardiac amyloidosis is poor. The median OS for the entire group was 35 months (95% CI: 7–67). The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One of the most common organs involved in AL is the heart, with 50–70% of patients clinically symptomatic at diagnosis. We conducted a multi-center, retrospective analysis of 67 patients diagnosed between July 2012 and August 2022 with the European 2012 modification of Mayo 2004 stage III cardiac AL. The most important factors identified in the univariate Cox analysis contributing to a longer OS included Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1, New York Heart Association functional classification (NYHA FC) ≤ 2, the use of autologous stem cell transplantation (ASCT) after induction treatment, achieving a hematological response (≥very good partial response) and cardiac (≥partial response) response after first-line treatment. The most important prognostic factors with the most significant impact on OS improvement in patients with modified Mayo stage III cardiac AL identified by multivariate Cox analysis are ECOG PS ≤ 1, NYHA FC ≤ 2, and achieving hematological response ≥ VGPR and cardiac response ≥ PR after first-line treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Teclistamab‐cqyv in multiple myeloma.

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
MULTIPLE myeloma, BISPECIFIC antibodies, PLASMA cells, PATIENT experience, DISEASE relapse, PLASMACYTOMA
Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Ivosidenib in acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Labanca, Caterina, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

43. Teclistamab‐cqyv in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

44. Tagraxofusp in myeloid malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

45. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study

Author

Malfona, Francesco, primary, Tanasi, Ilaria, additional, Piccini, Matteo, additional, Papayannidis, Cristina, additional, Federico, Vincenzo, additional, Mancini, Valentina, additional, Roncoroni, Elisa, additional, Todisco, Elisabetta, additional, Bianchi, Simona, additional, Ciotti, Giulia, additional, Chiusolo, Patrizia, additional, Gentile, Massimo, additional, Gianfelici, Valentina, additional, Giglio, Fabio, additional, Malagola, Michele, additional, Mulé, Antonino, additional, Saraceni, Francesco, additional, Vetro, Calogero, additional, Zallio, Francesco, additional, Cappelli, Luca Vincenzo, additional, Pizzolo, Giovanni, additional, Foà, Robin, additional, Bonifacio, Massimiliano, additional, and Chiaretti, Sabina, additional

Published
2023
Full Text
View/download PDF

46. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

47. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

Author

Avivi, Irit, primary, Vesole, David H., additional, Davila-Valls, Julio, additional, Usnarska-Zubkiewicz, Lidia, additional, Olszewska-Szopa, Magdalena, additional, Milunovic, Vibor, additional, Baumert, Bartłomiej, additional, Osękowska, Bogumiła, additional, Kopińska, Anna, additional, Gentile, Massimo, additional, Puertas-Martinez, Borja, additional, Robak, Paweł, additional, Crusoe, Edvan, additional, Rodriguez-Lobato, Luis Gerardo, additional, Gajewska, Małgorzata, additional, Varga, Gergely, additional, Delforge, Michel, additional, Cohen, Yael, additional, Gozzetti, Alessandro, additional, Pena, Camila, additional, Shustik, Chaim, additional, Mikala, Gabor, additional, Zalac, Klara, additional, Alexander, H. Denis, additional, Barth, Peter, additional, Weisel, Katja, additional, Martínez-López, Joaquín, additional, Waszczuk-Gajda, Anna, additional, Krzystański, Mateusz, additional, and Jurczyszyn, Artur, additional

Published
2023
Full Text
View/download PDF

49. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

50. Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy

Author

Morabito, Fortunato, primary, Adornetto, Carlo, additional, Monti, Paola, additional, Amaro, Adriana, additional, Reggiani, Francesco, additional, Colombo, Monica, additional, Rodriguez-Aldana, Yissel, additional, Tripepi, Giovanni, additional, D’Arrigo, Graziella, additional, Vener, Claudia, additional, Torricelli, Federica, additional, Rossi, Teresa, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Cutrona, Giovanna, additional, Gentile, Massimo, additional, and Greco, Gianluigi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results